SWANBIO THERAPEUTICS

Welcome to the Brand page for “SWANBIO THERAPEUTICS”, which is offered here for Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug and gene therapy discovery and drug/therapeutic development; biological research and development;swan bio therapeutics;therapeutic compositions comprised of adeno-associated viral (aav) vectors and recombinant adeno-associated viral (raav) vectors for therapeutic effect in gene therapy, gene inhibition therapy and/or rna interference (rnai); therapeutic compositions comprised of adeno-associated viral (aav) vectors and recombinant adeno-associated viral (raav) vectors for therapeutic effect in gene therapy, gene augmentation therapy; therapeutic compositions comprised of adeno-associated viral (aav) vectors and recombinant adeno-associated viral (raav) vectors for therapeutic effect in gene therapies using intrathecal administration; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate rna expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, gene delivery pharmaceuticals; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation; viruses, viral vectors and viral constructs for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, dna and/or rna therapeutics for the treatment of genetic disorders and neurological diseases and disorders;.

Its status is currently believed to be active. Its class is unavailable. “SWANBIO THERAPEUTICS” is believed to be currently owned by “SwanBio Therapeutics Limited”.